{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"40","value":"695.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Day -7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42","value":"576.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Maximum observed plasma concentration (Cmax) of PF-06463922 was observed directly from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"PK parameters of PF-06463922 were determined for a small subset of Phase 2 participants and Japan LIC. These participants received PF-06463922 100 mg orally QD and were combined into 1 reporting group for PK analysis. Japan LIC was not included in single-dose PK analysis, ie, they did not contribute to Day -7 data.","id":"OG000","title":"Phase 2 and Japan LIC PK Analysis Set"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number Analyzed\" signifies participants analyzed for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable for specified rows.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 and pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 15","title":"Maximum Observed Plasma Concentration (Cmax) of PF-06463922 (Phase 2)","type":"SECONDARY","unitOfMeasure":"ng/mL"}